ATE519847T1 - Il-17-homologe polypeptide und ihre therapeutische verwendung - Google Patents

Il-17-homologe polypeptide und ihre therapeutische verwendung

Info

Publication number
ATE519847T1
ATE519847T1 AT07016900T AT07016900T ATE519847T1 AT E519847 T1 ATE519847 T1 AT E519847T1 AT 07016900 T AT07016900 T AT 07016900T AT 07016900 T AT07016900 T AT 07016900T AT E519847 T1 ATE519847 T1 AT E519847T1
Authority
AT
Austria
Prior art keywords
polypeptides
present
therapeutic use
nucleic acid
homologue polypeptides
Prior art date
Application number
AT07016900T
Other languages
English (en)
Inventor
Jian Chen
Ellen Filvaroff
Sherman Fong
Audrey Goddard
Paul J Godowski
Christopher J Grimaldi
Austin L Gurney
Hanzhong Li
Kenneth J Hillan
Daniel Tumas
Lookeren Menno Van
Richard L Vandlen
Colin K Watanabe
P Mickey Williams
William I Wood
Daniel G Yansura
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/031274 external-priority patent/WO2000053752A2/en
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/en
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/en
Priority claimed from PCT/US2000/007532 external-priority patent/WO2000070050A1/en
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE519847T1 publication Critical patent/ATE519847T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
AT07016900T 1999-12-23 2000-12-20 Il-17-homologe polypeptide und ihre therapeutische verwendung ATE519847T1 (de)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US17209699P 1999-12-23 1999-12-23
PCT/US1999/031274 WO2000053752A2 (en) 1999-03-08 1999-12-30 Promotion or inhibition of angiogenesis and cardiovascularization
US17548100P 2000-01-11 2000-01-11
PCT/US2000/004341 WO2000053756A2 (en) 1999-03-08 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/005841 WO2000053758A2 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
US19100700P 2000-03-21 2000-03-21
PCT/US2000/007532 WO2000070050A1 (en) 1999-05-14 2000-03-21 Compositions and methods for the treatment of immune related diseases
PCT/US2000/015264 WO2000073452A2 (en) 1999-06-02 2000-06-02 Compositions and methods for the treatment of immune related diseases
US21380700P 2000-06-22 2000-06-22
US64484800A 2000-08-22 2000-08-22
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US24283700P 2000-10-24 2000-10-24
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
US25364600P 2000-11-28 2000-11-28
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
ATE519847T1 true ATE519847T1 (de) 2011-08-15

Family

ID=40140243

Family Applications (5)

Application Number Title Priority Date Filing Date
AT07016903T ATE541931T1 (de) 1999-12-23 2000-12-20 Il-17-homologe polypeptide und ihre therapeutische verwendung
AT07016899T ATE537258T1 (de) 1999-12-23 2000-12-20 Il-17-homologe polypeptide und ihre therapeutische verwendung
AT07016901T ATE541930T1 (de) 1999-12-23 2000-12-20 Il-17-homologe polypeptide und ihre therapeutische verwendung
AT07016900T ATE519847T1 (de) 1999-12-23 2000-12-20 Il-17-homologe polypeptide und ihre therapeutische verwendung
AT00989401T ATE444361T1 (de) 1999-12-23 2000-12-20 Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen

Family Applications Before (3)

Application Number Title Priority Date Filing Date
AT07016903T ATE541931T1 (de) 1999-12-23 2000-12-20 Il-17-homologe polypeptide und ihre therapeutische verwendung
AT07016899T ATE537258T1 (de) 1999-12-23 2000-12-20 Il-17-homologe polypeptide und ihre therapeutische verwendung
AT07016901T ATE541930T1 (de) 1999-12-23 2000-12-20 Il-17-homologe polypeptide und ihre therapeutische verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00989401T ATE444361T1 (de) 1999-12-23 2000-12-20 Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen

Country Status (10)

Country Link
EP (1) EP1240325B1 (de)
JP (10) JP5070117B2 (de)
AT (5) ATE541931T1 (de)
AU (1) AU2590901A (de)
CA (1) CA2391374A1 (de)
CY (1) CY1112334T1 (de)
DK (1) DK1240325T3 (de)
ES (7) ES2333772T3 (de)
PT (4) PT1897944E (de)
WO (1) WO2001046420A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
CA2401716A1 (en) * 2000-02-29 2001-09-07 Zymogenetics, Inc. Methods for promoting production of myelin by schwann cells
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
ES2317898T3 (es) * 2000-04-18 2009-05-01 Schering Corporation Usos medicinales de agonistas y antogonistas de il-174.
US20030092881A1 (en) * 2000-05-24 2003-05-15 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2427824A1 (en) * 2000-07-26 2002-01-31 Zymogenetics, Inc. Human cytokine receptor
EP1529843A3 (de) * 2000-08-11 2005-06-08 Eli Lilly & Company Neue sekretorische Proteine und ihre Verwendungen
EP1326974B1 (de) * 2000-10-13 2006-12-27 Eli Lilly And Company Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
WO2002038764A2 (en) * 2000-11-10 2002-05-16 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2842429A1 (en) * 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
WO2004024076A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP1572116A4 (de) * 2002-11-26 2007-12-12 Genentech Inc Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
US7749695B2 (en) * 2003-03-03 2010-07-06 Alexander Abbas PRO polypeptides for diagnosis of systemic lupus erythematosis
DK1641822T3 (da) * 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
EP1983000B1 (de) 2003-11-21 2015-09-02 UCB Biopharma SPRL Verfahren zur Behandlung von multipler Sklerose mittels Hemmung der IL-17-Aktivität
AU2005241020B2 (en) * 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
EP1765865A2 (de) 2004-06-10 2007-03-28 ZymoGenetics, Inc. Löslicher zcytor14, anti-zcytor14-antikörper und bindepartner sowie verfahren zur anwendung bei entzündungen
DE602005013805D1 (de) * 2004-09-21 2009-05-20 Merck Serono Sa Coinsins Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen
US20070053872A1 (en) * 2005-08-04 2007-03-08 Moore Emma E Treatment of wounds using il-17b
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
WO2008039553A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
JP2010509364A (ja) * 2006-11-08 2010-03-25 ザイモジェネティクス， インコーポレイテッド 創傷治癒における使用のためのｉｌ−１７ｂ
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
US20120107267A1 (en) 2009-03-11 2012-05-03 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
RU2537142C2 (ru) 2009-04-01 2014-12-27 Дженентек, Инк. Лечение нарушений, связанных с инсулинорезистентностью
GB0905972D0 (en) * 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
EP2427203B1 (de) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f-antikörper und deren verwendung
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2768859B1 (de) 2011-10-19 2018-02-21 MorphoSys AG Il17c-antagonisten zur behandlung von entzündungskrankheiten
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
KR20150050921A (ko) * 2013-11-01 2015-05-11 현대중공업 주식회사 폐열 회수용 연관식 보일러
CN107148283A (zh) 2014-10-31 2017-09-08 豪夫迈·罗氏有限公司 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
EP3250927B1 (de) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Genexpressionsmarker und behandlung von multipler sklerose

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2229264T5 (es) * 1995-03-23 2009-12-17 Immunex Corporation Receptor il-17.
CN1258315A (zh) * 1997-04-25 2000-06-28 津莫吉尼蒂克斯公司 哺乳动物细胞因子样因子7
AU8571198A (en) * 1997-07-16 1999-02-10 Human Genome Sciences, Inc. Interleukin-20
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
EP1015488B1 (de) * 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Interleukin-17 rezeptor-ähnliches protein
WO1999032632A1 (en) * 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
ES2292242T5 (es) * 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
WO2000042187A1 (en) * 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
KR20010089764A (ko) * 1999-01-11 2001-10-08 둘락 노먼 씨. 인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도
AU2596700A (en) * 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU3632600A (en) * 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
DE60034564T2 (de) * 1999-07-07 2007-12-27 Zymogenetics, Inc., Seattle Menschlicher cytokinrezeptor
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途

Also Published As

Publication number Publication date
JP2009159968A (ja) 2009-07-23
AU2590901A (en) 2001-07-03
ES2333772T3 (es) 2010-03-01
PT1897944E (pt) 2011-11-28
JP2009278996A (ja) 2009-12-03
JP2014239685A (ja) 2014-12-25
EP1240325A2 (de) 2002-09-18
HK1114635A1 (en) 2008-11-07
ATE444361T1 (de) 2009-10-15
HK1114636A1 (en) 2008-11-07
JP2012115275A (ja) 2012-06-21
HK1114634A1 (en) 2008-11-07
WO2001046420A3 (en) 2002-05-10
PT1240325E (pt) 2010-01-07
ES2379101T3 (es) 2012-04-20
JP2015007091A (ja) 2015-01-15
CA2391374A1 (en) 2001-06-28
DK1240325T3 (da) 2010-01-25
WO2001046420A2 (en) 2001-06-28
HK1114638A1 (en) 2008-11-07
HK1114637A1 (en) 2008-11-07
PT1897945E (pt) 2012-03-29
HK1150856A1 (en) 2012-01-13
JP2012152218A (ja) 2012-08-16
ATE541930T1 (de) 2012-02-15
ES2380812T3 (es) 2012-05-18
ES2380958T3 (es) 2012-05-21
ES2388748T3 (es) 2012-10-18
JP5070117B2 (ja) 2012-11-07
EP1240325B1 (de) 2009-09-30
JP2013165712A (ja) 2013-08-29
JP2010266454A (ja) 2010-11-25
PT1897947E (pt) 2012-03-29
JP2008278887A (ja) 2008-11-20
ES2506665T3 (es) 2014-10-13
CY1112334T1 (el) 2015-12-09
ES2458349T3 (es) 2014-05-05
WO2001046420A8 (en) 2002-07-04
ATE537258T1 (de) 2011-12-15
ATE541931T1 (de) 2012-02-15
JP5258691B2 (ja) 2013-08-07
JP2015077137A (ja) 2015-04-23

Similar Documents

Publication Publication Date Title
ATE541930T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
ATE449108T1 (de) Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure
ATE325815T1 (de) Menschliches neurotrimin-homolog
ATE310810T1 (de) Polypeptid und dafür kodierendes nukeinsäure
DK1366161T3 (da) Antagonist anti-PRO842-antistof
DE69939227D1 (de) Menschliches A33-Antigen-ähnliches Protein und dafür kodierende Nukleinsäure
ATE380864T1 (de) Menschliches prostasin-ähnliches protein und dafür kodierende nukleinsäure
DK1300417T3 (da) Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor
ATE404585T1 (de) Menschliches synaptogyrin-ähnliches protein und dafür kodierende nukleinsäure
ATE405590T1 (de) Menschliches hcar-ähnliches protein und dafür kodierende nukleinsäure
DE69926415D1 (de) Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren
DE69827532D1 (de) Polypeptide und dafür kodierende Nukleinsäure
DE60043258D1 (de) Menschliches suppressor von fused
DE69829417D1 (de) Polypeptide und dafür kodierende Nukleinsäure
DE60038986D1 (de) Ausgeschiedene und Transmembranpolypeptide und dafür kodierende Nukleinsäure
ATE363537T1 (de) Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure
DE60043242D1 (de) Ausgeschiedene und transmembrane Polypeptide und dafür kodierende Nukleinsäure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1897944

Country of ref document: EP